← Eichor
Condition: Refractory Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281Efficacy and Safety of Allium Ureteral Stent for Treating Refractory Ureteral Stricture
NA · 1 location(s) · En Chu Kong Hospital · NCT05455307Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565The Therapeutic Effect of Betaine in Syringomyelia
Phase 2 · 1 location(s) · Xuanwu Hospital, Beijing · NCT06308367A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012Efficacy of Behavioral Therapy for Chronic Refractory Cough
NA · 1 location(s) · Assiut University · NCT07488598A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07095075Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute
Phase 2 · 11 location(s) · ReAlta Life Sciences, Inc. · NCT06343792A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia
Phase N/A · 1 location(s) · Nantes University Hospital · NCT05983263Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
Phase 2 · 1 location(s) · University of Chicago · NCT06859164Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888Evaluation of the Efficacy of STNS With FAST and MULTIWAVE in Patients With Refractory Chronic Neuropathic Pain
NA · 1 location(s) · Poitiers University Hospital · NCT07154056MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943224A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT07545603NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
NA · 5 location(s) · Chinese University of Hong Kong · NCT04902248DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase 2 · 24 location(s) · Giselle Sholler · NCT04696029An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705Refractory Breathlessness in COPD
Phase N/A · 1 location(s) · Seoul National University · NCT07160322Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L
Phase 2 · 23 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03936153CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.